Donald J. Davidson

Company: Creative BioTherapeutics

Job title: Chief Executive Officer & Founder

Seminars:

Addressing Chemoresistance Using GRP-78 Inhibitors for Reduced Tumor Recurrence 3:15 pm

Outlining proposed mechanisms for chemoresistance in glioblastoma treatment including how glioblastoma cells under stress express GRP-78 on their surface, leading to the anchoring of proteins like PDL-1 and contributing to chemotherapy resistance Discussing the potential of GRP-78 inhibitors in blocking the tumor’s ability to anchor chemotherapy drug efflux pumps and other resistance-related proteins, thereby reducing…Read more

day: Conference Day 1